Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enigma Diagnostics, a point-of-care molecular diagnostics company, has received a grant of GBP1.8 million from the UK Government's Technology Strategy Board under the Technologies for Health program.
Subscribe to our email newsletter
The objective of the program is to develop a ‘gold-standard’ portable, rapid, automated DNA analysis (PRADA) molecular test system for the diagnosis of infectious diseases in decentralized and point-of-care settings such as GP surgeries. The focus of the program will be on sexually transmitted diseases including chlamydia and healthcare associated infections including methicillin-resistant Staphylococcus aureus.
The PRADA system development will be led by Enigma Diagnostics and is based on its proprietary technology. Researchers at the Centre for Healthcare Associated Infections at Nottingham University and Nottingham Trent University will develop and validate real-time molecular assays for the platform.
According to the company, the new PRADA system will allow rapid testing for emergency and out of hour’s admissions, allowing doctors to make quick decisions about how their patients are managed while reducing healthcare costs.
John McKinley, chairman of Enigma Diagnostics, said: “We are delighted to have received such substantial funding to support this project and to be working with two UK clinical partners. We are committed to delivering rapid, cost effective diagnostic systems that will substantially improve patient care and help eliminate the spread of infectious diseases.”